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Abstract: Human infections with the food-borne zoonotic pathogen Campylobacter jejuni are
progressively rising and constitute serious global public health and socioeconomic burdens.
Hence, application of compounds with disease-alleviating properties are required to combat
campylobacteriosis and post-infectious sequelae. In our preclinical intervention study applying an
acute C. jejuni induced enterocolitis model, we surveyed the anti-pathogenic and immune-modulatory
effects of the octapeptide NAP which is well-known for its neuroprotective and anti-inflammatory
properties. Therefore, secondary abiotic IL-10−/− mice were perorally infected with C. jejuni and
intraperitoneally treated with synthetic NAP from day 2 until day 5 post-infection. NAP-treatment
did not affect gastrointestinal C. jejuni colonization but could alleviate clinical signs of infection
that was accompanied by less pronounced apoptosis of colonic epithelial cells and enhancement
of cell regenerative measures on day 6 post-infection. Moreover, NAP-treatment resulted in less
distinct innate and adaptive pro-inflammatory immune responses that were not restricted to the
intestinal tract but could also be observed in extra-intestinal and even systemic compartments.
NAP-treatment further resulted in less frequent translocation of viable pathogens from the intestinal
tract to extra-intestinal including systemic tissue sites. For the first time, we here provide evidence
that NAP application constitutes a promising option to combat acute campylobacteriosis.
Keywords: NAP; activity-dependent neuroprotective protein (ADNP); anti-inflammatory effects;
immune-modulatory properties; Campylobacter jejuni; acute campylobacteriosis model; host–pathogen
interaction; gut–brain axis
1. Introduction
Human campylobacteriosis cases that are mainly caused by the zoonotric pathogens Campylobacter
jejuni and C. coli are progressively rising worldwide [1,2]. According to the European Centre for Disease
Prevention and Control (ECDC), C. jejuni has become the most commonly reported infectious agents
of bacterial gastroenteritis in the European Union (EU) since 2005 outcompeting Salmonella, Yersinia,
and pathogenic Escherichia coli [3]. Estimated disease-associated annual costs of 2.4 billion Euro in the
EU further underline the significant public health and socioeconomic burdens of campylobacteriosis [3].
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The spiral-shaped and highly motile Gram-negative bacteria usually reside within the intestinal tract of
warm-blooded vertebrates including avian livestock such as chicken and poultry as commensals and are
acquired by humans via the food chain upon consumption of contaminated meat or surface water [4–6].
Following establishment within the intestinal tract, the pathogens attach to and invade the colonic
epithelia cells, and subsequently induce pro-inflammatory innate and adaptive immune responses
leading to immune cell infiltrates, crypt abscesses, and ulcerations [7–9]. Following an incubation
period of 2–5 days, infected humans present with symptoms of varying degree that might mount in
the symptom complex of acute campylobacteriosis characterized by abdominal cramps, watery or
even bloody diarrheas with mucous discharge, and fever [10,11]. Whereas in the vast majority of cases
patients require, if at, symptomatic therapy such as replacement of fluids and electrolytes, antimicrobial
treatment might be indicated in individuals with immunosuppressive comorbidities [10,11]. Usually,
the course of the disease is self-limited and symptoms resolve within two weeks, but post-infectious
complications such as Guillain-Barré syndrome (GBS), reactive arthritis, and chronic inflammatory
morbidities in the intestinal tract might occur in rare instances [9–11].
Recently, our group has established an acute in vivo C. jejuni infection model providing a
reliable experimental tool to survey distinct molecules for their anti-pathogenic, anti-apoptotic,
anti-inflammatory, and cell-regenerative properties during campylobacteriosis on a pharmaceutical
level. Therefore, secondary abiotic interleukin (IL) 10−/− mice have been generated by broad-spectrum
antibiotic pre-treatment in order to overcome the physiological colonization resistance mediated by
the distinct murine gut microbiota composition which protects mice even from high-dose C. jejuni
infection [12–14]. Whereas conventional mice are approximately 10,000 times more resistant to both
lipopolysaccharide (LPS) and LOS as compared to humans [15], IL-10 gene deficiency renders mice
susceptible to these Toll-like receptor-4 (TLR-4) ligands [16]. In fact, within one week following
peroral C. jejuni challenge, secondary abiotic IL-10−/− mice suffer from wasting and bloody diarrhea
during this acute and non-self-limiting course of enterocolitis which is due to C. jejuni LOS induced
and TLR4 dependent immune responses within intestinal, extra-intestinal, and even systemic tissue
sites [16,17]. Our very recent pre-clinical intervention trials applying this clinical enterocolitis model
mimicking key features of human campylobacteriosis revealed that defined dietary molecules such
as carvacrol (abundant in thyme oil and oregano, for instance), but also distinct vitamins including
vitamin C and vitamin D could effectively alleviate C. jejuni induced disease due to their anti-apoptotic,
cell-regenerative, and immune-modulatory (i.e., anti-inflammatory) properties [18–20].
More than 20 years ago, the octapeptide NAP (i.e., NAPVSIPQ) has been identified as biologically
active fragment derived from the activity-dependent neuroprotective protein (ADNP) [21]. Human
ADNP is primarily expressed in both, the central and peripheral nervous system, but can also be found
in distinct compartments and cell populations of the immune system such as the spleen, macrophages,
and leukocytes, respectively [21–24]. The neuroprotective properties of NAP have been proven in vitro
and further confirmed in in vivo models for Alzheimer’s disease, stroke, fetal alcohol syndrome,
neonatal hypoxia, cerebral palsy, and closed head injury among others [21,25–30]. Particularly the
microtubules could be identified as the main target for NAP action [31], enlisting the microtubule
associated protein tau to microtubules upon direct interaction with the microtubule end binding
proteins, EB1 and EB2 [32,33]. Consequently, the cells can be protected from oxidative stress-induced
apoptosis [34]. Besides anti-oxidative mode of actions, immune-modulatory (i.e., anti-inflammatory)
effects have been proposed as mechanisms underlying the neuroprotective properties exerted by
NAP [35]. Importantly, the NAP target, EB1 is one of the major proteins with increased expression
following interferon-γ (IFN-γ)/LPS macrophage activation as part of the crucial impact of microtubules
on the immune response [36].
Our recent in vivo studies revealed that the anti-inflammatory effects of exogenous NAP were
not restricted to the nervous system but could also be observed in the intestinal tract given that
intraperitoneal application of NAP could effectively alleviate subacute and even acute small intestinal
inflammation in mice [37,38]. These NAP associated anti-inflammatory properties were further
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confirmed in an acute inflammation model affecting a different intestinal compartment and induced
by a different inflammatory stimulus, namely in acute colitis upon oral dextran sulfate sodium (DSS)
application to mice [39]. Given that information regarding potential health-beneficial effects of NAP in
infectious intestinal morbidities are lacking to date, we assessed the anti-pathogenic, anti-apoptotic,
cell-regenerative, and anti-inflammatory effects of the octapeptide in the intestinal tract (and beyond)
following exogenous NAP application to secondary abiotic IL-10−/− mice suffering from acute C. jejuni
induced enterocolitis in frame of our present preclinical intervention study.
2. Materials and Methods
2.1. Ethics Statement
All animal experiments were conducted in accordance with the European Guidelines for animal
welfare (2010/63/EU) following approval by the commission for animal experiments headed by the
“Landesamt für Gesundheit und Soziales” (LaGeSo, Berlin; on July 15, 2019, registration number
G0104/19). Twice a day, clinical conditions of mice were assessed.
2.2. Generation of Secondary Abiotic IL-10−/−Mice
Female and male IL-10−/− mice (all in C57BL/10 background) were reared under specific pathogen
free (SPF) conditions in the same unit of the Forschungseinrichtungen für Experimentelle Medizin
(FEM, Charité-University Medicine Berlin). Mice were maintained in cages including filter tops within
an experimental semi-barrier (accessible only with lab coat, overshoes, caps, and sterile gloves) under
standard conditions (22–24 ◦C room temperature, 55± 15% humidity, 12 h light/12 h dark cycle) and had
free access to autoclaved standard chow (food pellets: ssniff R/M-H, V1534-300, Sniff, Soest, Germany).
In order to deplete the gut microbiota, 3-week-old littermates were transferred into sterile cages
(maximum of 4 animals per cage) and subjected to a broad-spectrum antibiotic treatment for eight weeks
by adding ampicillin plus sulbactam (1 g/L; Ratiopharm, Ulm, Germany), vancomycin (500 mg/L; Cell
Pharm, Hannover, Germany), ciprofloxacin (200 mg/L; Bayer Vital, Leverkusen, Germany), imipenem
(250 mg/L; Fresenius Kabi, Bad Homburg, Germany) and metronidazole (1 g/L; B. Braun, Melsungen,
Germany) to the drinking water (ad libitum) as described earlier [12,40]. Secondary abiotic IL-10−/−
mice were continuously kept and handled under strict aseptic conditions and received autoclaved
food and drinking water in order to minimize the risk of contaminations.
2.3. C. jejuni Infection, Gastrointestinal Colonization, and Extra-Intestinal Translocation
For infection experiments, C. jejuni strain 81–176 that had initially been isolated from a diseased
patient suffering from bloody diarrhea was freshly cultivated on Columbia agar (supplemented with
5% sheep blood) and Karmali agar plates (both from Oxoid, Wesel, Germany) after thawing from a
stock. On two consecutive days (i.e., days 0 and 1), secondary abiotic IL-10−/− mice were perorally
challenged with 109 colony forming units (CFU) in a volume of 0.3 mL phosphate buffered saline (PBS;
Thermo Fisher Scientific, Waltham, MA, USA) by gavage [12]. In order to assess intestinal colonization
properties C. jejuni loads were quantitatively surveyed in fecal samples over time post-infection (p.i.)
and furthermore, in luminal samples derived from distinct parts of the gastrointestinal tract (i.e., from
the stomach, duodenum, ileum, and colon) upon necropsy on day 6 post-infection (p.i.) by culture
as stated elsewhere [12]. In brief, serial dilutions of samples were plated onto Columbia agar plates
containing 5% sheep blood and Karmali agar plates (both from Oxoid, Wesel, Germany) and incubated
in a jar under microaerophilic conditions for 48 h at 37 ◦C. For assessment of bacterial translocation to
extra-intestinal compartments respective ex vivo biopsies were homogenized with a sterile pistil and
serial dilutions cultivated accordingly. Furthermore, cardiac blood (0.2 mL) was immediately streaked
onto Karmali agar plates.
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2.4. Treatment with Synthetic NAP
The octapeptide NAP was synthesized as described earlier [41]. Starting on day 2 p.i. and lasting
until the end of the experiment mice were either treated with synthetic NAP (1.0 mg per kg body
weight; dissolved in NaCl 0.9%) or received vehicle (placebo) once daily via the intraperitoneal route.
A potential antimicrobial effect of the solutions was excluded as reported earlier [38].
2.5. Clinical Assessment
Before and after pathogen infection, we quantitatively surveyed the clinical conditions of mice
on a daily basis by using a standardized cumulative clinical score (maximum 12 points), addressing
the clinical aspect/wasting (0: normal; 1: ruffled fur; 2: less locomotion; 3: isolation; 4: severely
compromised locomotion, pre-final aspect), the abundance of blood in feces (0: no blood; 2: microscopic
detection of blood by the Guajac method using Haemoccult, Beckman Coulter/PCD, Germany;
4: macroscopic blood visible), and stool consistency (0: formed feces; 2: pasty feces; 4: liquid feces)
as described earlier [42]. Fecal blood positivity rates were assessed by the ratio of microscopically
(including macroscopically) fecal blood positive mice and the total number of analyzed animals.
2.6. Sampling Procedures
On day 6 p.i., groups of mice were sacrificed by CO2 asphyxiation. Ex vivo biopsies from
mesenteric lymph nodes (MLN), spleen, liver, kidneys, lungs, colon, and ileum as well as luminal
gastrointestinal samples including stomach, duodenum, ileum, and colon were taken under sterile
conditions. For serum cytokine measurements cardiac blood was taken. Large and small intestinal
samples were collected from each mouse in parallel for microbiological, immunohistopathological,
and immunological analyses.
2.7. Immunohistochemistry
In situ immunohistochemical analyses were done in large intestinal ex vivo biopsies following
immediate fixation in 5% formalin and embedding in paraffin as recently reported [42,43]. In brief,
in order to detect apoptotic epithelial cells, proliferation epithelial cells, macrophages/monocytes,
T lymphocytes, regulatory T cells, and B lymphocytes, 5 µm thin colonic paraffin sections were stained
with primary antibodies directed against cleaved caspase-3 (Asp175, Cell Signaling, Beverly, MA, USA,
1:200), Ki67 (TEC3, Dako, Glostrup, Denmark, 1:100), F4/80 (no. 14-4801, clone BM8, eBioscience,
San Diego, CA, USA, 1:50), CD3 (no. N1580, Dako, 1:10), FOXP3 (clone FJK-165, no. 14-5773,
eBioscience, 1:100), and B220 (no. 14-0452-81, eBioscience; 1:200), respectively. Positively stained cells
were quantitated by a blinded independent investigator applying light microscopy (magnification 100×
and 400×). The average number of respective positively stained cells in each sample was determined
within at least six high power fields (HPF, 0.287 mm2, 400×magnification).
2.8. Pro-Inflammatory Cytokines in Intestinal, Extra-Intestinal, and Serum Samples
Distal large and small intestinal ex vivo biopsies were cut longitudinally, washed in PBS (Thermo
Fisher Scientific) and strips of approximately 1 cm2 tissue as well as ex vivo biopsies derived from
MLN (3 lymph nodes), liver (approximately 1 cm3), kidney (one half after longitudinal cut) and
lung were placed into 24-flat-bottom well culture plates (Thermo Fisher Scientific) containing 500 µL
serum-free RPMI 1640 medium (Thermo Fisher Scientific) supplemented with penicillin (100 U/mL)
and streptomycin (100 µg/mL; Biochrom, Berlin, Germany). After 18 h at 37 ◦C, respective culture
supernatants as well as serum samples were tested for interferon-γ (IFN-γ), tumor necrosis factor
(TNF), monocyte chemoattractant protein-1 (MCP-1), and IL-6 by the mouse inflammation cytometric
bead array (CBA; BD Biosciences, Germany) on a BD FACSCanto II flow cytometer (BD Biosciences).
Nitric oxide concentrations were assessed by the Griess reaction [44].
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2.9. Statistical Analysis
Medians and levels of significance were determined with GraphPad Prism v8, USA. The Student’s
t-test was used for pairwise comparisons of normally distributed data, whereas the Mann–Whitney test
was used for pairwise comparisons of not normally distributed data. For multiple comparisons,
the one-sided ANOVA with Tukey post-correction was used for normally distributed data
and the Kruskal–Wallis test with Dunn’s post-correction for not normally distributed data.
Two-sided probability (p) values ≤ 0.05 were considered significant. Data were pooled from four
independent experiments.
3. Results
3.1. Gastrointestinal Pathogen Loads Following NAP Treatment of C. jejuni Infected Secondary Abiotic
IL-10−/− Mice
Secondary abiotic IL-10−/− mice were perorally challenged with 109 viable C. jejuni strain 81–176
on days 0 and 1 and intraperitoneally treated with synthetic NAP or placebo once daily from day 2
until day 5 p.i. Cultural analyses revealed that irrespective of the treatment regimen C. jejuni could
stably establish within the murine intestines as indicated by median loads of 109 bacterial cells per g
feces (Figure S1). Upon necropsy on day 6 p.i., pathogen loads were comparable in distinct parts of
the gastrointestinal tract such as stomach, duodenum, ileum and colon of NAP and placebo treated
mice (n.s.; Figure 1). Hence, intraperitoneal NAP application did not affect colonization efficiencies of
C. jejuni upon peroral infection of secondary abiotic IL-10−/− mice.
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Figure 1. Gastrointestinal pathogen loads following NAP treatment of C. jejuni infected secondary
abiotic IL10−/− mice. On day (d) 0 and d1 secondary abiotic IL10−/− mice were perorally infected with
C. jejuni strain 81-176 by gavage and treated intraperitoneally with either synthetic NAP (open circles) or
placebo (PLC; closed circles) from d2 until d5. Upon necropsy on day 6 post-infection, luminal bacterial
loads were quantitatively assessed in distinct gastrointestinal compartments by culture (in colony
forming units per g; CFU/g) as indicated. Medians (black bars) and numbers of analyzed animals (in
parentheses) are given. Data were pooled from four independent experiments.
3.2. Clinical Conditions Following NAP Treatment of C. jejuni Infected Secondary Abiotic IL10−/− Mice
In order to quantitatively survey the clinical effects of either treatment regimen over time we
applied an stablished clinical coring system [42]. As early as th ee days following the initial NAP
cation (i.e., day 5 p. .), mice were le s clinically compromised as compared to placebo controls
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(p < 0.05–0.001; Figure S2). On day 6 p.i., mice from the control group were suffering from severe
campylobacteriosis, whereas NAP treated mice displayed lower clinical scores for overall clinical
conditions and for wasting, abundance of fecal blood, and diarrhea in particular (p < 0.01–0.001;
Figure 2). Hence, NAP treatment alleviated clinical signs of C. jejuni infection.
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Figure 2. Clinical conditions following NAP treatment of C. jejuni infected secondary abiotic IL10−/−
mice. On day (d) 0 and d1 secondary abiotic IL10−/− mice were perorally infected with C. jejuni strain
81–176 by gavage and treated intraperitoneally with either synthetic NAP (open circles) or placebo (PLC;
closed circles) from d2 until d5. On d6 post-infection, (A) the overall clinical conditions, (B) wasting,
(C) fecal blood, and (D) st l consistency were quantitatively assessed applying a standardized clinical
scoring system. Naive mice served a negative control (open diamonds). Medians (black bars), levels of
significance (p-values) a d termined by the Kruskal–W llis test a d Dunn’s post-correction and number
of analyzed animals (in parentheses) are given. Data were pooled from four independent experiments.
3.3. Colonic Epithelial Apoptotic and Proliferative Cell Responses following NAP Treatment of C. jejuni Infected
Secondary Abiotic IL10−/− Mice
Since apoptosis is considered as reliable parameter for the grading of intestinal inflammatory
conditions [12], we enumerated the numbers of apoptotic cells in colonic epithelia following
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immunohistochemical staining of large intestinal paraffin sections with an antibody directed against
cleaved caspase-3 (Casp3). Upon necropsy, increased numbers of Casp3+ colonic epithelial cells
were assessed (p < 0.001), but with much lower counts in NAP as compared to placebo treated mice
(p < 0.001; Figure 3A). Conversely, higher numbers of Ki67+ cells indicative for cell proliferation and
regeneration could be determined in colonic epithelia of the NAP versus the control cohort on day 6
p.i. (p < 0.005; Figure 3B). Hence, NAP treatment resulted in less pronounced apoptotic cell responses
in large intestines upon C. jejuni infection but promoted cell regenerative measures counteracting
pathogen induced cell damage.
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Figure 3. Colonic epithelial apoptotic and proliferative cell responses following NAP treatment of
C. jejuni infected secondary abiotic IL10−/− mice. On day (d) 0 and d1 secondary abiotic IL10−/−
mice were perorally infected with C. jejuni strain 81-176 by gavage and treated intraperitoneally
with either synthetic NAP (open circles) or placebo (PLC; closed circles) from d2 until d5. On d6
post-infection, the average numbers of colonic epithelial (A) apoptotic (Casp3+) and (B) proliferating
(Ki67+) cells were microscopically a sessed in six h gh power fields (HPF, 400× magnificatio ) per
mouse in immunohistochemically stai ed colonic paraffin sections. Naive mice serv d as negative
controls (open diamonds). Medians (black bars), levels of significance (p-values) as determined by the
Kruskal–Wallis test and Dunn’s post-correction or the one-way ANOVA test and Tukey’s post-correction,
as well as numbers of analyzed mice (in parentheses) are indicated. Data were pooled from four
independent experiments.
3.4. Colonic Innate and Adaptive Im une Cell Responses following NAP Treatment of C. jejuni Infected
Secondary Abiotic IL10-/- Mice
We next surveyed potential immune-modulatory properties of exogenous NAP during C. jejuni
infection. Therefore, numbers of distinct innate and adaptive immune cell populations were determined
in large intestinal paraffin sections applying in situ immunohistochemistry. C. jejuni infection was
accompanied by increased abundances of innate immune cells such as F4/80+ macrophages and
monocytes in the colonic mucosa and lamina propria (p < 0.001 vs. naive), but with lower counts in
NAP as compared to placebo treated mice on day 6 p.i. (p < 0.001; Figure 4A). In addition, C. jejuni
infected mice displayed higher colonic numbers of adaptive immune cell populations including CD3+
T lymphocytes, FOXP3+ regulatory T cells and B220+ B lymphocytes as compared t naive control
animals (p < 0.001; Figure 4B–D). On day 6 p.i., B lymphocyte counts were lower in the colonic mucosa
and lamina propria of NAP as compared to placebo treated mice, however (p < 0.05; Figure 4D).
Notably, a trend towards lower large intestinal T lymphocytes and higher regulatory T cells could be
observed following NAP versus placebo application but did not reach statistical significance due to
high standard deviations in respective groups (n.s.; Figure 4B,C). Hence, exogenous NAP resulted in
less distinct innate and adaptive immune responses upon C. jejuni infection.
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numbers of (A) macrophages and monocytes (F4/80+), (B) T lymphocytes (CD3+), (C) regulatory T cells
(FOXP3+), and (D) B lymphocytes (B220+) were microscopically assessed in six high power fields (HPF,
400×magnification) per mouse i immunohistochemically stained olonic paraffin secti s. N ive mice
served as negative controls (open diamonds). Medians (black bars), levels of significance (p-values) as
determi ed by the one-w y ANOVA test and Tukey’s post-correction or the Kruskal–Wallis test and
Dunn’s post-correction, as well as numbers of analyzed mice (in parentheses) are indicated. Data were
pooled from four independent experiments.
3.5. Intestinal Pro-Inflammatory Mediator Secretion following NAP Treatment of C. jejuni Infected Secondary
Abiotic IL10−/− Mice
We next assessed pro-inflammatory mediator secretion in intestinal compartments following NAP
treatment of C. jejuni infected mice. On day 6 p.i., increased nitric oxide and TNF concentrations
could be measured in colonic ex vivo biopsies (p < 0.001; Figure 5A,C). These increases were, however,
less pronounced in NAP as compared to placebo treated mice (p < 0.01 and p < 0.005, respectively;
Figure 5A,C). Whereas colonic IFN-γ concentrations were multifold elevated in the placebo cohort on
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day 6 p.i. (p < 0.001), those measured in NAP treated mice did not differ from naive control animals
(n.s.; Figure 5B). In MLN draining the inflamed intestines, less distinct nitric oxide and IFN-γ secretion
was assessed upon NAP versus placebo treatment on day 6 p.i. (p < 0.05 and p < 0.01, respectively;
Figure 5D,E), whereas a trend towards lower TNF concentrations was observed in the former versus
the latter regimen (n.s.; Figure 5F). In addition, immune-modulatory properties of exogenous NAP
were also effective in the distal small intestines as indicated by lower IFN-γ, TNF, MCP-1, and IL-6
concentrations in ex vivo biopsies obtained from the ileum of NAP versus placebo treated mice on day
6 p.i. (p < 0.05–0.005; Figure S3). Hence, exogenous NAP dampens C. jejuni induced pro-inflammatory
mediator secretion in different parts of the intestinal tract.
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Figure 5. Intestinal pro-inflammatory mediator secretion following NAP treatment of C. jejuni infected
secondary abiotic IL10−/− mice. On day (d) 0 and d1 secondary abiotic IL10−/− mice were perorally
infected with C. jejuni strain 81–176 by gavage and treated intraperitoneally with either synthetic NAP
(open circles) or placebo (PLC; closed circles) from d2 until d5. On d6 post-infection, nitric oxide (A,D),
IFN-γ (B,E), and TNF (C,F) concentrations were measured in ex vivo biopsies taken from colon (A–C)
and mesenteric lymph nodes (MLN; D–F). Naive mice served as negative controls (open diamonds).
Medians (bl ck bars), l vels of significance (p-value ) as determined by the Kruskal–Wallis t st and
Dunn’s post-correction, as well as numbers of analyzed mice (in parentheses) are indicated. Data were
pooled from four independent experiments.
3.6. Extra-Intestinal including Systemic Pro-Inflammatory Mediator Secretion following NAP Treatment of
C. jejuni Infected Secondary Abiotic IL10−/− Mice
We further addressed whether the inflammation-dampening effects of exogenous NAP were
restricted to the intestinal tract or could also be observed in extra-intestinal compartments. Therefore,
we measured pro-inflammatory mediators in ex vivo biopsies taken from liver, kidneys and lungs
(Figure 6A–I). In fact, IFN-γ concentrations were lower in liver, kidneys and lungs of NAP as
compared to placebo treated mice on day 6 p.i. (p < 0.005; Figure 6B,E,H), which also held true
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for nitric oxide concentrations measured in kidneys and lungs (p < 0.05–0.01; Figure 6D,G) and for
hepatic TNF concentrations (p < 0.05; Figure 6C). Strikingly, the anti-inflammatory properties of NAP
application were also effective systemically given that TNF, MCP-1, and IL-6 concentrations were
all lower in serum samples taken from NAP versus placebo treated mice on day 6 p.i. (p < 0.005;
Figure 7). Hence, NAP ameliorated C. jejuni induced pro-inflammatory immune response also in
extra-intestinal—including systemic—compartments.
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infected secondary abiotic IL10−/− mice. On day (d) 0 and d1 secondary abiotic IL10−/− mice were
perorally infected with C. jejuni strain 81-176 by gavage and treated intraperitoneally with either
synthetic NAP (open circles) or placebo (PLC; closed circles) from d2 until d5. On d6 post-infection,
nitric oxide (A,D,G), IFN-γ (B,E,H), and TNF (C,F,I) concentrations were measured in ex vivo biopsies
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test and Dunn’s post-correction, as well as numbers of analyzed mice (in parentheses) are indicated.
Data were pooled from four independent experiments.
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Figure 7. Systemic pro-inflammatory mediator secretion following NAP treatment of C. jejuni infected
secondary abiotic IL10−/− mice. On day (d) 0 and d1 secondary abiotic IL10−/− mice were perorally
infected with C. jejuni strain 81-176 by gavage and treated intraperitoneally with either synthetic
NAP (open circles) or placebo (PLC; closed circles) from d2 until d5. On d6 post-infection, (A) IFN-γ,
(B) TNF, (C) MCP-1, and (D) IL-6 concentrations were measured in serum samples. Naive mice served
as negative controls (open diamonds). Medians (black bars) and levels of significance (p-values) as
determined by the Kruskal–Wallis test and Dunn’s post-correction, as well as numbers of analyzed
mice (in parentheses) are indicated. Data were pooled from four independent experiments.
3.7. Bacterial Translocation following NAP Treatment of C. jejuni Infected Secondary Abiotic IL10-/- Mice
We finally addressed whether viable bacteria were translocating from the infected intestines
to extra-intestinal including systemic tissue sites of NAP treated mice. Whereas the pathogenic
translocations rates to MLN of NAP and placebo treated mice were comparable on day 6 p.i. (58.8%
and 61.5%, respectively; Figure 8A), C. jejuni could be cultured from liver, kidneys, lungs, and
spleen of placebo control mice in 17.7%, 23.5%, 11.8%, and 23.5% of cases, respectively (Figure 8B–E),
Microorganisms 2020, 8, 802 12 of 18
but less frequently in 0%, 0%, 7.7%, and 0% of respective compartments taken from NAP treated mice
(Figure 8B–E). Of note, all cardiac blood samples were culture-negative for C. jejuni (Figure 8F). Hence,
NAP treatment resulted in less frequent translocation of viable pathogens from the intestinal tract to
extra-intestinal sites, including systemic compartments.
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Figure 8. Bacterial translocation following NAP treatment of C. jejuni infected secondary abiotic IL10−/−
mice. On day (d) 0 and d1 secondary abiotic IL10−/− mice were perorally infected with C. jejuni strain
81-176 by gavage and treated intraperitoneally with either synthetic NAP (open bars) or placebo
(PLC; closed bars) from d2 until d5. On d6 post-infection, the abundance of C. jejuni was assessed
in ex vivo biopsies derived from (A) mesenteric lymph nodes (MLN), (B) liver, (C) kidney, (D) lung,
(E) spleen, and (F) cardiac blood by culture. Naive mice served as negative controls. The cumulative
relative translocation rate of viable pathogens into the respective compartment out of four independent
experiments (in %) as well as the numbers of culture-positive mice out of the total number of animals
(in parentheses) are indicated.
4. Discussion
Since antimicrobial resistance has become a major concern for public health in general and also
Campylobacter bec me increasingly resistant to clinically important antibiotics [45], it is of utmost
relevance to search for novel antibiotics-independent approaches to combat and/or even to prevent from
campylobacteriosis. Our present preclinical intervention trial is the first study providing convincing
evidence for disease-alleviating effects of the octapeptide NAP during acute colitis of enteropathogenic
origin. Following intraperitoneal injections of synthetic NAP on four consecutive days secondary
abiotic IL-10−/− mice that had been perorally infected with C. jejuni, (i) harbored the pathogen in
their gastrointestinal tract at comparable loads alike placebo control mice, but were (ii) clinically
less compromised and (iii) displayed less distinct apoptotic, but (iv) enhanced cell proliferative and
regenerative responses in colonic epithelia. Furthermore, following NAP as compared to placebo
treatment, (v) lower numbers of both innate and adaptive immune cell subsets infiltrating the colonic
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mucosa and lamina propria could be assessed that were accompanied by (vi) less pronounced secretion
of pro-inflammatory mediators in distinct intestinal, extra-intestinal, and strikingly, even systemic
compartments; and finally, (vii) by less frequent translocation of viable pathogens from the intestinal
tract to extra-intestinal tissue sites.
The result of uncompromised gastrointestinal colonization properties of the pathogen following
synthetic NAP application was rather expected since our proceeding in vitro tests revealed that neither
the verum nor the placebo working solutions exerted any antimicrobial effects [38]. Whereas placebo
treated mice were suffering from severe campylobacteriosis, exogenous NAP resulted in an overall
better clinical outcome and in less distinct wasting and bloody diarrhea in particular. In support,
also in our previous studies applying different experimental model of intestinal inflammation, mice
from the NAP treatment cohort had benefitted clinically and were suffering from less severe subacute
ileitis following Toxoplasma gondii infection of mice with a human gut microbiota [37], which also
held true for acute T. gondii induced ileitis [38] and acute DSS induced colitis [39] of conventional
mice. The disease-alleviating effects of exogenous NAP were also effective on microscopic level given
that mice were suffering from less severe C. jejuni induced colonic apoptosis, which was also the
case when assessing numbers of cleaved caspase-3+ epithelial cell in the ileum and colon of mice
suffering from acute T. gondii induced ileitis [38] or acute DSS colitis [39], respectively. In support,
the prevention of caspase-3 activation and of subsequent apoptotic cell death highlighted the cell
survival promoting features of NAP in the central nervous system [34,46]. Conversely, numbers
of Ki67+ intestinal epithelial cells were increased following NAP treatment thereby promoting cell
regenerative measures counteracting induced cell damaging responses as shown in our present
and previous reports applying different acute intestinal inflammation models [38,39]. Interestingly,
in a child suffering from the autistic ADNP syndrome (driven by heterozygous ADNP mutations)
skin biopsies showed decreased Ki67+ staining, potentially associated with defective wound healing.
Indeed, in a culture model of wound healing with cells derived from the mutated-ADNP skin biopsy,
NAP showed protective effects [47]. In this respect, Adnp haploinsuffient mice (Adnp+/−) mimicked
some of the skin deficient ADNP syndrome phenotype [47] and further showed distinct microbiota
changes which were ameliorated by NAP treatment [48], potentially, through immune-modulatory
effect. Given the gut microbiota changes towards higher loads of commensal bifidobacteria which
are regarded as anti-inflammatory and probiotic bacterial species as observed in our previous NAP
treatment studies applying mice harboring a murine or human gut microbiota [37,39,48], we will
address the triangle relationship (“ménage à trois”) between C. jejuni, host commensal gut bacteria,
and host immunity in future surveys.
Here, NAP exerted potent immune-modulatory effects since in the verum cohort far less innate
as well as adaptive immune cells had accumulated in the colonic mucoasa and lamina propria of
C. jejuni infected mice as compared to placebo controls. Furthermore, less pronounced secretion of
pro-inflammatory mediators such as IFN-γ, TNF, IL-6, MCP-1, and nitric oxide (exerting oxidative
stress to the intestinal epithelium) could be assessed in distinct intestinal compartments including
the colon, ileum, and MLN draining the inflamed intestines of NAP versus placebo treated mice.
In support, comparable NAP associated anti-inflammatory effects within the intestinal tract were
observed in acute T. gondii induced ileitis and DSS colitis of mice [38,39]. Interestingly, monocytes,
and T and B lymphocytes derived from peripheral blood mononuclear cells of healthy blood donors
were shown to express ADNP [35]. Upon NAP treatment reduced T cell proliferation and activation
could be observed in vitro which was accompanied by decreased secretion of pro-inflammatory
cytokines including IFN-γ [35]. Furthermore, NAP effectively suppressed TNF and IL-6 secretion in
murine macrophages in vitro [24] and of TNF in head trauma in vivo [27].
Remarkably, the inflammation-dampening effects of exogenous NAP were not restricted to the
intestinal tract but could also be observed in extra-intestinal compartments as indicated by lower
IFN-γ, TNF, and nitric oxide concentrations measured in liver, lung, and kidney ex vivo biopsies.
Strikingly, the potent anti-inflammatory properties were also effective systemically given that IFN-γ,
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TNF, MCP-1, and IL-6 serum concentrations were lower upon NAP as compared to placebo treatment
of C. jejuni infected mice. In support, in both, acute T. gondii ileitis and acute DSS colitis less pronounced
extra-intestinal pro-inflammatory mediator secretion could be assessed following NAP as compared to
placebo treatment [38,39] which also held true for systemic anti-inflammatory effects observed in acute
murine ileitis [38].
Whereas ADNP is supposed to be a secreted protein [22,49–51], NAP is hypothesized to exhibit
its systemic immune-modulatory functions in a cytokine-like (i.e., paracrine or apocrine) fashion [23].
Importantly, the NAP target, EB1 is one of the major proteins with increased expression
following IFN-γ/LPS macrophage activation as part of the microtubules’ crucial impact on the
immune response [36]. In this respect, macrophages display significant heterogeneity and plasticity.
IFN-γ, LPS, and Bacillus Calmette-Guerin (BCG) induce the M1 phenotype, secreting a large number
of pro-inflammatory cytokines (e.g., TNF, IL-6, IL-12), while transforming growth factor β (TGF-β)
or glucocorticoids activate alternative pathways differentiating macrophages into the M2 phenotype,
which exhibit increased secretion of IL-10, promote angiogenesis, wound healing, and regulate
inflammatory responses [52]. Macrophage activation involves dramatic morphological changes in cell
shape due to the rearrangement of actin and microtubules [53]. Furthermore, EB1/EB2 bind transient
receptor potential cation channel subfamily M member 4 (Trpm4) possibly affecting T cell/Th1-Th2
activation, with Th1 secreting IFN-γ [54]. Given the ADNP/EB1/microtubules interactions, these
findings indicate immune modulations by ADNP/NAP. Indeed, NAP inhibited LPS-induced secretion
of TNF, IL-6, and IL-12 from ADNP-expressing macrophages [24] and increased the polymerized
microtubules network area in neuronal-like cells [55]. Importantly and most relevant to the current
study, NAP protected C57BL/6j mice that were perorally infected with Toxoplasma gondii and developed
acute ileitis due to Th1-type immune responses [38].
Furthermore, here, translocation of viable pathogens from the infected intestines to extra-intestinal
tissue sites such as liver, kidney, and spleen occurred in none of the NAP as opposed to the placebo
treated C. jejuni infected mice indicative for a less compromised epithelial barrier function in the
former versus the latter. Even though all cardiac blood samples remained culture negative for C. jejuni
irrespective of the treatment cohort, one needs to take into consideration that distinct soluble C. jejuni
cell wall constituents with immunogenic potency such as LOS among others might have circulated
and contributed to the hyper-inflammatory scenario observed in placebo control mice.
The significant disease-alleviating effects upon NAP treatment are even more remarkable when
considering that the synthetic octapeptide was administered only four times to mice. Hence, it is
tempting to speculate that the effects would have even been more pronounced following increased
doses, higher frequencies of application and start even before C. jejuni infection. The effects of such a
prophylactic regimen will be addressed in future studies.
Our recent preclinical intervention studies further underlined the reliability of the here applied
acute C. jejuni infection model in order to assess potential anti-pathogenic, anti-apoptotic, and
immune-modulatory properties of promising candidate molecules in vivo. Secondary abiotic IL-10−/−
mice that had been pre-treated with vitamin C or carvacrol, for instance, harbored lower colonic
pathogen loads and were suffering from less severe enterocolitis upon C. jejuni infection as compared
to placebo control animals. Additionally, these treatment regimens dampened apoptotic epithelial and
pro-inflammatory immune cell responses in the intestines that were accompanied by less pronounced
pro-inflammatory cytokine secretion [19,20]. Potent immune-modulatory properties during acute
C. jejuni induced enterocolitis could also be achieved by peroral application of vitamin D starting
before C. jejuni infection [18].
In summary, we here show for the first time that exogenous NAP exerts potent disease-alleviating
effects during acute murine enterocolitis caused by an enteropathogen such as C. jejuni. We conclude
that synthetic NAP might be a promising novel option for treating acute campylobacteriosis in humans.
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ADNP Activity-dependent neuroprotective protein
BCG Bacillus Calmette–Guerin
Casp3 Caspase-3
CBA Cytometric Bead Array
CFU Colony forming units
DSS Dextran sulfate sodium
ECDC European Centre for Disease Prevention and Control
EU European Union
GBS Guillain–Barré syndrome





MCP-1 Monocyte chemoattractant protein-1
MLN Mesenteric lymph nodes
PBS Phosphate buffered saline
p.i Post-infection
PLC Placebo
SPF Specific pathogen free
TGF-β Transforming growth factor β
TLR-4 Toll-like receptor 4
TNF Tumor necrosis factor
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